Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. Learn more about PROCYSBI (cysteamine bitartrate) delayed-release capsules and delayed-release oral granules, the first and only cystine-depleting therapy with 12-hour dosing approved for the management of nephropathic cystinosis in adults & children 1 year of age and older. PROCYSBI is contraindicated in patients with serious hypersensitivity reaction, including anaphylaxis to penicillamine or cysteamine. PROCYSBI granules or “microbeads” are composed of cysteamine bitartrate surrounded by an acid-resistant enteric coating. The coating allows the cysteamine bitartrate to pass through the acidic stomach to the alkaline small intestine, where the microbeads dissolve and release cysteamine gradually to provide 12 hours of continuous cystine control. See additional Important Safety Information and Full Prescribing Information in the resource section or visit PROCYSBIhcp.com. P-PYB-US-00040 04/22